Compare HRMY & BKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | BKD |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2020 | 2005 |
| Metric | HRMY | BKD |
|---|---|---|
| Price | $41.14 | $11.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $44.11 | $15.10 |
| AVG Volume (30 Days) | 849.5K | ★ 3.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | 0.07 |
| Revenue | $868,453,000.00 | ★ $4,531,426,000.00 |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | $4.30 |
| P/E Ratio | ★ $22.37 | $158.14 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $7.97 |
| 52 Week High | $43.49 | $17.09 |
| Indicator | HRMY | BKD |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 26.62 |
| Support Level | $40.92 | $10.71 |
| Resistance Level | $43.38 | $11.17 |
| Average True Range (ATR) | 1.21 | 0.35 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 40.51 | 11.75 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.